Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?계산 스크리닝을 사용한 COVID-19에 대한 약물 용도 : Fostamatinib/R406은 잠재적 후보입니까?Article Published on 2022-07-012022-08-31 Journal: Methods (San Diego, Calif.) [Category] [DOI] 10.1016/j.ymeth.2021.08.007 PMC 바로가기 [Article Type] Article
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label studyClinical Trial Published on 2022-06-012022-10-05 Journal: American journal of hematology [Category] [DOI] 10.1002/ajh.26508 PMC 바로가기 [Article Type] Clinical Trial
Drug repurposing improves disease targeting 11-fold and can be augmented by network module targeting, applied to COVID-19약물 용도는 11 배의 질병을 향상시키고 Covid-19에 적용되는 네트워크 모듈 표적에 의해 강화 될 수 있습니다.Article Published on 2021-10-192022-08-31 Journal: Scientific Reports [Category] [DOI] 10.1038/s41598-021-99721-y PMC 바로가기 [Article Type] Article
High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages초기 인간 항-SARS-CoV-2 IgG의 높은 역가 및 낮은 푸코실화는 폐포 대식세포에 의한 염증을 촉진합니다Research Article Published on 2021-05-112022-09-12 Journal: Science Translational Medicine [Category] [DOI] 10.1126/scitranslmed.abf8654 PMC 바로가기 [Article Type] Research Article
Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial경증 또는 중등도의 COVID-19 폐렴으로 입원한 환자를 위한 염증 신호 억제제(MATIS)의 다군 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-04-122022-09-10 Journal: Trials [Category] [DOI] 10.1186/s13063-021-05190-z PMC 바로가기 [Article Type] Letter
Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential TherapeuticArticle Published on 2021-03-152023-07-02 Journal: The Journal of Infectious Diseases [Category] [DOI] 10.1093/infdis/jiaa789 PMC 바로가기
Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung InjurySARS-CoV-2 유발 급성 폐 손상을 퇴치하기 위해 Fostamatinib 용도 변경Preview Published on 2020-11-172022-09-10 Journal: Cell Reports Medicine [Category] [DOI] 10.1016/j.xcrm.2020.100145 PMC 바로가기 [Article Type] Preview
Clinical Trial to Evaluate an Approved ITP Therapy Targeting Spleen Tyrosine Kinase (SYK) for Prevention and Treatment of COVID-19 Related ComplicationsConference abstract Published on 2020-11-042022-10-05 Journal: Blood [Category] [DOI] 10.1182/blood-2020-141045 [Article Type] Conference abstract
A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury뮤신-1 감소 화합물에 대한 고함량 선별 검사를 통해 포스타마티닙을 급성 폐 손상의 신속한 용도 변경 후보로 확인Article Published on 2020-10-292022-09-11 Journal: Cell Reports Medicine [Category] [DOI] 10.1016/j.xcrm.2020.100137 PMC 바로가기 [Article Type] Article
A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic뮤신-1 감소 화합물에 대한 고함량 검사를 통해 포스타마티닙이 COVID-19 대유행 기간 동안 급성 폐 손상에 대한 신속한 용도 변경을 위한 후보로 확인됨Article Published on 2020-06-302022-09-11 Journal: bioRxiv [Category] [DOI] 10.1101/2020.06.30.180380 PMC 바로가기 [Article Type] Article